Forecast

The analysts' average price target is €73.71 (-2.31%). The median is €95.77 (+26.93%).

News Go to news feed

Agilon Health significantly beats Q2 expectations and raises full‑year outlook

Agilon Health reported adjusted earnings of $1.04 per share in Q2 2026 (expectation $0.08) and revenue of $1.49 billion (expectation $1.44 billion), and subsequently raised its full‑year guidance for revenue, medical margin and adjusted EBITDA. The medical margin rose to $197 million and adjusted EBITDA to $70 million, despite a deliberate 12.3% reduction in Medicare Advantage membership. Management attributes the strong results to stricter contract discipline, improved risk adjustments and favorable cost trends. The stock jumped sharply and the company now expects about $5.8 billion in revenue and roughly $85 million of adjusted EBITDA for 2026. » More on de.investing.com

In the last quarter, Agilon Health Inc had revenue of €1.31B and net profit of €15.73M